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Abstract
Background: Congenital hyperinsulinism (CHI) is the most frequent cause of hypoglycemia in children. In addition
to increased peripheral glucose utilization, dysregulated insulin secretion induces profound hypoglycemia and
neuroglycopenia by inhibiting glycogenolysis, gluconeogenesis and lipolysis. This results in the shortage of all
cerebral energy substrates (glucose, lactate and ketones), and can lead to severe neurological sequelae. Patients
with CHI unresponsive to medical treatment can be subjected to near-total pancreatectomy with increased risk of
secondary diabetes. Ketogenic diet (KD), by reproducing a fasting-like condition in which body fuel mainly derives
from beta-oxidation, is intended to provide alternative cerebral substrates such ketone bodies. We took advantage
of known protective effect of KD on neuronal damage associated with GLUT1 deficiency, a disorder of impaired
glucose transport across the blood-brain barrier, and administered KD in a patient with drug-unresponsive CHI,
with the aim of providing to neurons an energy source alternative to glucose.
Methods: A child with drug-resistant, long-standing CHI caused by a spontaneous GCK activating mutation
(p.Val455Met) suffered from epilepsy and showed neurodevelopmental abnormalities. After attempting various
therapeutic regimes without success, near-total pancreatectomy was suggested to parents, who asked for other
options. Therefore, we proposed KD in combination with insulin-suppressing drugs.
Results: We administered KD for 2 years. Soon after the first six months, the patient was free of epileptic crises,
presented normalization of EEG, and showed a marked recover in psychological development and quality of life.
Conclusions: KD could represent an effective treatment to support brain function in selected cases of CHI.
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Background
Congenital hyperinsulinism (CHI) is the most frequent
cause of hypoglycemia in children [1, 2]. Mutations that
affect insulin secretion regulation by the three main clas-
ses of energy substrates, i.e. glucose, aminoacids, and
free fatty acids (FFA) [2, 3], can cause CHI that requires
rapid diagnosis and treatment to limit/avoid neuronal
damage [4] and the irreversible neurological sequelae
consequent to prolonged, severe hypoglycemia. Neurons in
the superficial layers of cerebral cortex and hippocampus
are those preferentially affected by lack of glucose,
followed by neurons in basal ganglia and thalamus [5].
However, mild, recurrent hypoglycemia can cause hip-
pocampal synaptic dysfunction even in absence of neur-
onal damage [6, 7]. These experimental findings explain
why memory, learning, intelligence and attention are
the cognitive domains most vulnerable to hypoglycemia
in children with type 1 diabetes [8, 9]. Although glucose
is the main energy source for neurons, human brain
can also utilize ketone bodies from FFA, lactate, pyru-
vate, glycerol and some aminoacids, as alternative sub-
strate [10]. The protective effect of ketone bodies on
hypoglycemia-induced neuronal damage has been dem-
onstrated in animal studies [11, 12] and also in patients
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with type 1 diabetes, in whom the ingestion of medium-
chain triglycerides prevented the cognitive deficit in-
duced by hypoglycemia by elevating blood levels of
3-hydroxybutyrate [13]. Ketogenic diet (KD), which
provides FFA as alternative fuel to carbohydrates for
neuronal energy metabolism, has therefore a strong
potential neuroprotective effect. The main indication
of KD in children is the treatment of refractory epi-
lepsy, but it is also the causal therapy of GLUT1 defi-
ciency, a metabolic disorder characterized by epilepsy,
developmental delay and movement disorders [14, 15]. In
GLUT1 deficiency, neuroglycopenia that ensues as conse-
quence of the impaired glucose transport across the
blood-brain barrier [14, 15] is effectively improved by KD
that provides ketone bodies as alternative energy source
for the brain. In CHI, excessive insulin secretion not only
induces severe neuroglycopenia, but also halts, by inhibit-
ing gluconeogenesis, glycogenolysis and lipolysis, the use
of other metabolic pathways that provide energetic sub-
strates to the neurons. Other inherited metabolic dis-
eases, such as mitochondrial fatty oxidation defects,
share the same neurological risk of hypoglycemia be-
cause of lack of ketones [16]. Therefore, developing
brain of patients with CHI is more vulnerable than
other forms of hypoglycemia. Based on the similarities
of brain metabolism perturbation shared by GLUT1
deficiency and CHI, we attempted to tackle neuroglyco-
penic symptoms and outcome by administering KD in a
patient with severe, drug-resistant form of CHI.
Methods
We report a case of severe persistent hyperinsulinemic
hypoglycemia due to a “de novo” mutation in GCK. The
girl presented with hypoglycemic seizures since the first
years of life. Family history was positive for type 2 dia-
betes. From the age of 2 years, she was admitted to the
hospital for recurrent episodes of severe hypoglycemia
(up to 1.5 mmol/L, normal value 3.9–5.5 mmol/L [17])
associated to cold sweating, seizures and hypotonia. At
the age of 3 years laboratory tests were performed and
showed hypoglycemia with hyperinsulinemia (blood glu-
cose 1.95–2.3 mmol/L; plasma insulin 5.5–10.2 μUI/ml).
EEG showed abnormal waves in the left hemisphere and
epileptogenic abnormalities, and treatment with valpro-
ate was started. Genetic investigation for ABCC8 and
KNCJ11 performed elsewhere was negative. At 9 years of
age the patient was referred to our hospital, and the
heterozygous p.Val455Met mutation was found at GCK
gene sequencing [18]; parents showed wild type GCK se-
quence. At admission, the child was receiving a combin-
ation of high-dose diazoxide (12 mg/kg/day) and octreotide
(15 μg/kg/day), with no apparent clinical response. Previ-
ously, a trial with nifedipine (up to 0.75 mg/kg/day) had
been attempted without benefit. We gradually increased
octreotide to 50 μg/kg/day in combination with diazoxide
(10 mg/kg/day) but observed persistence of hypoglycemia
and epilepsy. A further association with slow-release carbo-
hydrate to drugs did not elicit any clinical improvement,
and the patient continued to present hypoglycemic episodes
(0.5–1.6 mmol/L), seizures and absence epilepsy regardless
of glycemic values, that required frequent hospitalizations.
Despite a mild improvement of neurologic symptoms after
switch from valproate therapy to ethosuccimide, absence
epilepsy and evident EEG abnormalities persisted, even in
the intercritical phases; her intellectual function was bor-
derline. Furthermore, at the age of 10 years the patient
quickly gained 11.5 kg within 12 months, becoming mildly
obese (BMI z-score: >97th centile). Overall, her quality of
life was very poor. The lack of response to drug therapy
with risk of permanent and severe brain sequelae made us
to consider a near-total pancreatectomy, that was discussed
with parents with the warning of no guarantee to achieve
normoglycemia and of the increased hazard of secondary
diabetes. At parents’ request to avoid surgery, we then pro-
posed a trial with KD, explaining that it was aimed to pre-
vent neuroglycopenic epilepsy and to improve neurological
status by providing ketone bodies as an alternative energy
source for neurons, as seen in GLUT1 deficiency. Consent
was obtained from patient and parents after full explanation
of the objective. With the new dietary regimen we provided
85 % of energy from lipids, 8 % from proteins, and 7 %
from glucose of a normocaloric diet divided in 5 meals. De-
termination of blood ketones (Nova StatStrips® Glucose
Ketone Meter, Nova Medical, Menarini Diagnostics,
Florence, Italy) in the morning (after overnight fast of
10–12 h) and in the evening (after dinner) was utilized
as guidance to establish the ratio of lipids: proteins plus
carbohydrates. The ratio was progressively increased
every three months from 1.5:1 to 3:1 during the first
year of KD in order to obtain a blood ketone concen-
tration close to 4 mmol/L [19]. First assessment of the
KD outcome was performed as inpatient; auxological
evaluation, hepatic and renal function, plasma glucose, in-
sulin, lactate, FFA, blood ketones and lipid profile, along
with renal tubular function and abdomen ultrasound were
assessed every 6 months. Follow-up included 96 to 120-h
long continue glucose monitoring (CGM- ipro2, Med-
tronic; data analysis by MiniMed software, Medtronic,
MiniMed, Northridge, CA, USA®) [20] with EEG per-
formed simultaneously. Weschsler Intelligence scale
for Children (WISC III: third edition) and Vineland
Adaptive Behavior Scale were serially administered to
evaluate cognitive and adaptive abilities.
Results and discussion
While on KD the patient continued diazoxide and octreo-
tide treatment (10 mg/kg/day and 35 μg/kg/day, respect-
ively). Six months after KD was started, maintenance of
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blood ketones between 2–5 mmol/L (Fig. 1, panel a) fully
resolved neuroglycopenic signs with parallel disappear-
ance of both epileptic crisis and absence epilepsy, despite
blood glucose levels permanently below 5.5 mmol/L even
after meal, and close to 2.2–2.7 mmol/L most of time
(Fig. 1, panel b). EEG improved and became normal
within the first year on KD, showing no alteration even
during episodes of hypoglycemia (Fig. 2). During the
first 6 months of KD the patient lost 9 kg and her BMI
normalized. Psychological evaluation revealed a strength-
ening of social, cognitive and verbal capacities (Fig. 3).
The child and her family reported an improvement of
physical and psychosocial well-being, reduction of fear of
hypoglycemic symptoms and awareness of a lower risk
of neurological injury, with an overall amelioration of
the quality of life related to the management of disease.
Diazoxide was discontinued, and currently the patient
is given octreotide, reduced to 25 μg/kg/day, without
Fig. 1 Blood ketones and glucose levels during KD. Ketones progressively raised up to 2–5 mmol/L while increasing the KD ratio from 1.5:1
to 3:1 (Panel a). 120h-continuous glucose monitoring on KD at 2 weeks, 3 months, 6 months, 12 months showing persistence of hypoglycemia
(mean 52 mg/dl, 2.8 mmol/L, range 40–84 mg/dl, 2.2–4.6 mmol/L) (Panel b)
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any neuroglycopenic symptoms. KD was well tolerated
over a period of 24 months, with no side-effects and no
changes in laboratory tests.
GCK activation caused by gain-of-function mutations
determines an increased affinity for glucose and lowers
the glucose thresholds for insulin release in the pancre-
atic beta cell, giving rise to CHI [18, 20–23]. Most pa-
tients bearing a GCK mutation have relatively mild
disease, easily managed with diazoxide, but a few cases
with a severe phenotype, who were subjected to near-
total pancreatectomy to avoid neurological sequelae,
have been described [24, 25]. Although V455M mutation
has been previously associated with a mild phenotype
[18], our patient displayed a drug-resistant form, with a
steep increase of BMI in peripubertal age and a clinical
course resembling that described in a patient with the
GCK/A456V mutation [26]. Prompted by patient’s long-
standing symptoms, drug resistance and the preference
of parents to avoid demolitive surgery, we opted for a
KD trial to provide an energy source to central nervous
system (CNS) alternative to glucose, on the bases of its
proven efficacy for the treatment of GLUT1 deficiency
[14]. We thus challenged the central tenet of treatment
of CHI patients, which is to maintain normoglycemia to
avoid irreversible brain damage [4]. As a matter of fact,
neurological sequelae are more prevalent in CHI than in
other forms of hypoglycemia because of the inhibition of
lipolysis and ketogenesis by inappropriately high insulin
Fig. 2 Comparison between cerebral activity and glycemia before and after 1 year of KD. Disappearance of absence epilepsy or electrical signs
despite hypoglycemia. Before KD, long monitoring EEG showed generalized spike and waves discharges with loss of contact during hypoglycemia. On
KD, long monitoring EEG appeared normal, with absence of ictal EEG and epileptic manifestations even during hypoglycemia
Fig. 3 Cognitive an adaptive skills before and after 1 year of KD. Normalization of cognitive, social and verbal capacities on KD. Weschsler
Intellingence Scale for Children (WISCIII): normal >80, borderline 70–80; Vineland Adaptive Behavior Scale (VABS): moderately high 116–130,
normal 85–115, moderately low 70–84
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levels [16]. Ketogenic diet, by restricting the amount of
carbohydrates along with a significant increase of fat in-
take, reproduces a fasting-like condition in which metab-
olism is shifted from glycolysis to beta-oxidation of FFA
and ketone bodies formation for ATP synthesis [27]. In
our patient we observed that after the beginning of KD
neurological symptoms, psychological development and
epilepsy manifestations all improved, despite the persist-
ence of hyperinsulinemic hypoglycemia. The neuropro-
tective effect of ketone bodies has been associated with
the activation of a several endogenous metabolic and
genetic programs that stabilize and/or enhance cellular
metabolism [27], increasing cerebral ATP and reducing
neuronal excitability. In addition, KD decreases mTOR
activity in neuronal cells, thus conferring anticonvulsant
effect [28]. Of note, KD reverted EEG pathologic pat-
terns in our patient even during hypoglycemia (Fig. 2).
This result highlights the protective effect of KD on
CNS despite persistence of neuroglycopenia. Cognitive
and adaptive development also improved after the first
six months of KD, further confirming its positive effect.
Bearing in mind that ketone bodies have additional neu-
roprotective effects acting as ROS scavengers [11], and
by inducing PPARα and UCP2 expression [29], and inhi-
biting glutamate uptake into synaptic vesicles [30], we
hypothesize that KD might have prolonged positive ef-
fects on brain function.
CNS protective action of 3-hydroxybutyrate has been
successfully exploited to treat hypoglycemic coma in rats
[31] and multiple acyl-CoA dehydrogenase deficiency in
humans [32]. Consequently, we suggest that the utilization
of 3-hydroxybutyrate may be a safer option and an area of
investigation in specific patients, such neonates with CHI,
in whom administration of KD might be hazardous.
Conclusions
The clinical and neurological improvement observed in
our patient with CHI suggests that KD could have a
neuroprotective effect despite persistence of neuroglyco-
penia. Additional studies are needed to confirm the effi-
cacy of this novel therapeutic approach in selected CHI
cases to support brain function by providing an alterna-
tive energy source to CNS.
Abbreviations
CHI: Congenital hyperinsulinism; KD: Ketogenic diet; GCK: Glucokinase;
GLUT1: Glucose transporter 1; EEG: Electroencephalography; FFA: Free fatty
acids; ROS: Radical oxygen species ; CNS: Central nervous system.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AM conceptualized and designed the study, collected, coordinated and
supervised data collection and analysis, drafted the initial manuscript,
and approved the final manuscript as submitted. LM contributes to data
collection, drafted the initial manuscript, reviewed and revised the
manuscript, and approved the final manuscript as submitted. FB carried out
genetic analysis, drafted the initial manuscript, critically revised the
manuscript and approved the final manuscript as submitted. SB and GG
designed the nutritional regimen, drafted the initial manuscript, and
approved the final manuscript as submitted. RC performed the
neurophysiological studies, drafted the initial manuscript, and approved the
final manuscript as submitted. SC performed cognitive evaluation, drafted
the initial manuscript, and approved the final manuscript as submitted. CDV
conceptualized the study, gave a substantial contribution in data analysis,
drafted the initial manuscript, critically reviewed the manuscript and
approved the final manuscript as submitted. All authors approved the final
manuscript as submitted and agree to be accountable for all aspects of the
work. Questions related to the accuracy or integrity of any part of the work
were appropriately investigated and resolved from all authors.
Author details
1Metabolic Unit, Department of Pediatric Medicine, Bambino Gesù Children’s
Hospital, piazza S. Onofrio 4, 00165 Rome, Italy. 2Department of Experimental
Medicine, University of Tor Vergata and Bambino Gesù Children’s Hospital,
Rome, Italy. 3Clinical Nutrition, Gastroenterology Department, Bambino Gesù
Children’s Hospital, Rome, Italy. 4Neurology, Neuroscience Department,
Bambino Gesù Children’s Hospital, Rome, Italy. 5Psychology Unit,
Neuroscience Department, Bambino Gesù Children’s Hospital, Rome, Italy.
Received: 23 June 2015 Accepted: 10 September 2015
References
1. Arnoux JB, de Lonlay P, Ribeiro MJ, Hussain K, Blankenstein O, Mohnike K, et al.
Congenital hyperinsulinism. Early Hum Dev. 2010;86(5):287–94.
2. Hussain K, De Lonlay P. Hyperinsulinism. In: Blau N, Duran M, Gibson KM,
Dionisi-Vici C, editors. Physician’s Guide to the Diagnosis, Treatment, and
Follow-Up of Inherited Metabolic Diseases. Berlin Heidelberg: Springer-
Vergal; 2014. p. 323–36.
3. Li C, Buettger C, Kwagh J, Matter A, Daikhin Y, Nissim IB, et al. A signaling
role of glutamine in insulin secretion. J Biol Chem. 2004;279(14):13393–401.
4. Menni F, de Lonlay P, Sevin C, Touati G, Peigne C, Barbier V, et al.
Neurologic outcomes of 90 neonates and infants with persistent
hyperinsulinemic hypoglycemia. Pediatrics. 2001;107(3):476–9.
5. Auer RN, Hugh J, Cosgrove E, Curry B. Neuropathologic findings in three
cases of profound hypoglycemia. Clin Neuropathol. 1989;8(2):63–8.
6. McNay EC, Williamson A, McCrimmon RJ, Sherwin RS. Cognitive and neural
hippocampal effects of long-term moderate recurrent hypoglycemia.
Diabetes. 2006;55(4):1088–95.
7. Yamada KA, Rensing N, Izumi Y, De Erausquin GA, Gazit V, Dorsey DA, et al.
Repetitive hypoglycemia in young rats impairs hippocampal long-term
potentiation. Pediatr Res. 2004;55(3):372–9.
8. Ryan C, Gurtunca N, Becker D. Hypoglycemia: a complication of diabetes
therapy in children. Pediatr Clin North Am. 2005;52(6):1705–33.
9. Blasetti A, Chiuri RM, Tocco AM, Di Giulio C, Mattei PA, Ballone E, et al. The
effect of recurrent severe hypoglycemia on cognitive performance in
children with type 1 diabetes: a meta-analysis. J Child Neurol.
2011;26(11):1383–91.
10. Suh SW, Hamby AM, Swanson RA. Hypoglycemia, brain energetics, and
hypoglycemic neuronal death. Glia. 2007;55(12):1280–6.
11. Haces ML, Hernandez-Fonseca K, Medina-Campos ON, Montiel T, Pedraza-
Chaverri J, Massieu L. Antioxidant capacity contributes to protection of ketone
bodies against oxidative damage induced during hypoglycemic conditions.
Exp Neurol. 2008;211(1):85–96.
12. Yamada KA, Rensing N, Thio LL. Ketogenic diet reduces hypoglycemia-
induced neuronal death in young rats. Neurosci Lett. 2005;385(3):210–4.
13. Page KA, Williamson A, Yu N, McNay EC, Dzuira J, McCrimmon RJ, et al.
Medium-chain fatty acids improve cognitive function in intensively treated
type 1 diabetic patients and support in vitro synaptic transmission during
acute hypoglycemia. Diabetes. 2009;58(5):1237–44.
14. Veggiotti P, De Giorgis V. Dietary Treatments and New Therapeutic
Perspective in GLUT1 Deficiency Syndrome. Curr Treat Options Neurol.
2014;16(5):291.
15. Pearson TS, Akman C, Hinton VJ, Engelstad K, De Vivo DC. Phenotypic
spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS).
Curr Neurol Neurosci Rep. 2013;13(4):342.
Maiorana et al. Orphanet Journal of Rare Diseases  (2015) 10:120 Page 5 of 6
16. Gataullina S, Dellatolas G, Perdry H, Robert JJ, Valayannopoulos V, Touati G, et al.
Comorbidity and metabolic context are crucial factors determining
neurological sequelae of hypoglycaemia. Dev Med Child Neurol.
2012;54(11):1012–7.
17. Thornton PS, Stanley CA, De Leon DD, Harris D, Haymond MW, Hussain K, et al.
Recommendations from the Pediatric Endocrine Society for Evaluation
and Management of Persistent Hypoglycemia in Neonates, Infants, and
Children. J Pediatr. 2015;167(2):238–45.
18. Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, et al. Familial
hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med.
1998;338(4):226–30.
19. Gilbert DL, Pyzik PL, Freeman JM. The ketogenic diet: seizure control correlates
better with serum beta-hydroxybutyrate than with urine ketones.
J Child Neurol. 2000;15(12):787–90.
20. Maiorana A, Barbetti F, Boiani A, Rufini V, Pizzoferro M, Francalanci P, et al.
Focal congenital hyperinsulinism managed by medical treatment: a diagnostic
algorithm based on molecular genetic screening.Clin Endocrinol (Oxf).
2014;81(5):679-88.
21. Christesen HB, Tribble ND, Molven A, Siddiqui J, Sandal T, Brusgaard K, et al.
Activating glucokinase (GCK) mutations as a cause of medically responsive
congenital hyperinsulinism: prevalence in children and characterisation of a novel
GCK mutation. Eur J Endocrinol. 2008;159(1):27–34.
22. Meissner T, Marquard J, Cobo-Vuilleumier N, Maringa M, Rodriguez-Bada P,
Garcia-Gimeno MA, et al. Diagnostic difficulties in glucokinase hyperinsulinism.
Horm Metab Res. 2009;41(4):320–6.
23. Dullaart RP, Hoogenberg K, Rouwe CW, Stulp BK. Family with autosomal
dominant hyperinsulinism associated with A456V mutation in the
glucokinase gene. J Intern Med. 2004;255(1):143–5.
24. Sayed S, Langdon DR, Odili S, Chen P, Buettger C, Schiffman AB, et al.
Extremes of clinical and enzymatic phenotypes in children with
hyperinsulinism caused by glucokinase activating mutations. Diabetes.
2009;58(6):1419–27.
25. Cuesta-Munoz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Nanto-
Salonen K, Rahier J, et al. Severe persistent hyperinsulinemic hypoglycemia
due to a de novo glucokinase mutation. Diabetes. 2004;53(8):2164–8.
26. Christesen HB, Jacobsen BB, Odili S, Buettger C, Cuesta-Munoz A, Hansen T,
et al. The second activating glucokinase mutation (A456V): implications for
glucose homeostasis and diabetes therapy. Diabetes. 2002;51(4):1240–6.
27. Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet.
Epilepsia. 2007;48(1):43–58.
28. McDaniel SS, Rensing NR, Thio LL, Yamada KA, Wong M. The ketogenic diet
inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia.
2011;52(3):e7–11.
29. Diano S, Matthews RT, Patrylo P, Yang L, Beal MF, Barnstable CJ, et al.
Uncoupling protein 2 prevents neuronal death including that occurring
during seizures: a mechanism for preconditioning. Endocrinology.
2003;144(11):5014–21.
30. Juge N, Gray JA, Omote H, Miyaji T, Inoue T, Hara C, et al. Metabolic control
of vesicular glutamate transport and release. Neuron. 2010;68(1):99–112.
31. Schutz PW, Struys EA, Sinclair G, Stockler S. Protective effects of d-3-
hydroxybutyrate and propionate during hypoglycemic coma: clinical and
biochemical insights from infant rats. Mol Genet Metab. 2011;103(2):179–84.
32. Van Hove JL, Grunewald S, Jaeken J, Demaerel P, Declercq PE,
Bourdoux P, et al. D, L-3-hydroxybutyrate treatment of multiple acyl-
CoA dehydrogenase deficiency (MADD). Lancet. 2003;361(9367):1433–5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Maiorana et al. Orphanet Journal of Rare Diseases  (2015) 10:120 Page 6 of 6
